At SITC, we are convinced that new, clinically relevant immuno-oncology innovations with the potential for marked clinical impact are imminent. Learn more about our three-year strategic plan here: https://lnkd.in/g66MdvWx #SITCquestfor100 #immunotherapy
Society for Immunotherapy of Cancer (SITC)’s Post
More Relevant Posts
-
Our commentary summarizes the CGT industry views on PAT articulated during a virtual event and documents key takeaways on the benefits and barriers to PAT. It also notes the unique considerations for PAT in the context of CGTs and highlights some near-term options to help you accelerate these important therapies to patients before implementing PAT. You can download the PDF for free here 👉🏻 https://okt.to/tUOBpj #biophorum #cellandgenetherapy #genetherapies
To view or add a comment, sign in
-
Head on over to the #CSF today to view the latest full slide deck, which covers a study by Taylor, et al. They presented the results of contRAst 3, a 24-week, phase III, multicentre, randomised controlled trial that compared the safety and efficacy of otilimab with sarilumab and placebo. The primary objective was to assess the proportion of patients achieving ACR20 at Week 12. They concluded that otilimab did not achieve ACR20, nor were there any significant improvements in secondary endpoints versus placebo. Furthermore, otilimab did not demonstrate non-inferiority to sarilumab. Don’t forget The CSF is completely free and will keep you up to date with the latest research findings in #RhematoidArthritis. https://ow.ly/6seV50PZBtb
To view or add a comment, sign in
-
-
Join Dr. Young Wang, MD, and Dr. Ingela Mauritzon, PhD, on Wednesday, February 14 at 12:00 PM ET, as they guide you through the intricacies of in vitro diagnostics (IVD). This live webinar addresses the pressing need for standardized regulatory practices in the field of IVDs as advancements are made in an increasingly interconnected global healthcare landscape and demand grows for more precise diagnostics. Enroll today (with or without contact hours) > https://bit.ly/3RV3Sm5 #ACRP #Webinar #ContinuingEducation #InVitroDiagnostics #IVD
To view or add a comment, sign in
-
-
Want to stay up to date with all the latest in the world of cardio metabolic therapeutics and clinical data? Head on over to the CMF, where we have just posted our latest detailed slide decks. This month includes a systematic review and meta-analysis of randomised controlled trials (n=6) reporting safety outcomes in elderly patients with T2D treated with SGLT2i’s by Rigato, et al. Read the detailed slide deck and get all the latest insights for only on the #CMF: https://ow.ly/qhmu50PFjC1
Cardiometabolic Forum
cardiometabolicforum.com
To view or add a comment, sign in
-
Join #SITC for the FREE Summit on Immunomodulation of ADCs on June 26. Discussion topics include the impact of ADCs on the immune system, clinical considerations surrounding ADCs, ADC combination therapies, and next generation immunoconjugates. Register: https://lnkd.in/gmgcVAd9
To view or add a comment, sign in
-
-
Market Research Associate | Technology Research | Competitive Intelligence | Data Analytics | Clinical Trial Analysis | Business Consulting | Patent Analysis
𝐇𝐞𝐩𝐚𝐭𝐨𝐫𝐞𝐧𝐚𝐥 𝐒𝐲𝐧𝐝𝐫𝐨𝐦𝐞 (𝐇𝐑𝐒) 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 Our latest market report on Hepatorenal Syndrome (HRS) offers foundational insights into the technologies driving HRS diagnostics and therapeutics, emphasizing innovative solutions for precision in diagnosing and treating renal failure linked to chronic liver disease. The report presents a strategic framework for comprehensive HRS management, integrating diverse diagnostic methods and safety protocols to address healthcare challenges. The report highlights cutting-edge innovations in HRS technologies and explores the latest advancements in diagnostic techniques and therapeutic approaches. A global scenario analysis evaluates the worldwide implementation of HRS diagnostic tools, identifying emerging trends and investment prospects. Gain valuable insights into groundbreaking advances and patents in HRS diagnostics, market opportunities and challenges, current and future trends, pipeline progress, ongoing technological trials, and profiles of key players shaping HRS research. 𝐑𝐞𝐩𝐨𝐫𝐭 𝐋𝐢𝐧𝐤: https://lnkd.in/g-ijdPVs 𝐀𝐬𝐤 𝐟𝐨𝐫 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧: https://lnkd.in/d6q8Q-5a #HepatorenalSyndrome #HRS #MedicalInnovation #RenalFailure #LiverDisease #HealthcareAdvancements #MedicalResearch #ClinicalTrials #HRSMarketReport #SyndicateReport #HRSMarketAnalysis #MarketReport
𝐇𝐞𝐩𝐚𝐭𝐨𝐫𝐞𝐧𝐚𝐥 𝐒𝐲𝐧𝐝𝐫𝐨𝐦𝐞 (𝐇𝐑𝐒) 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 Our latest market report on Hepatorenal Syndrome (HRS) offers foundational insights into the technologies driving HRS diagnostics and therapeutics, emphasizing innovative solutions for precision in diagnosing and treating renal failure linked to chronic liver disease. The report presents a strategic framework for comprehensive HRS management, integrating diverse diagnostic methods and safety protocols to address healthcare challenges. The report highlights cutting-edge innovations in HRS technologies and explores the latest advancements in diagnostic techniques and therapeutic approaches. A global scenario analysis evaluates the worldwide implementation of HRS diagnostic tools, identifying emerging trends and investment prospects. Gain valuable insights into groundbreaking advances and patents in HRS diagnostics, market opportunities and challenges, current and future trends, pipeline progress, ongoing technological trials, and profiles of key players shaping HRS research. 𝐑𝐞𝐩𝐨𝐫𝐭 𝐋𝐢𝐧𝐤: https://lnkd.in/g-ijdPVs 𝐀𝐬𝐤 𝐟𝐨𝐫 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧: https://lnkd.in/d6q8Q-5a #HepatorenalSyndrome #HRS #MedicalInnovation #RenalFailure #LiverDisease #HealthcareAdvancements #MedicalResearch #ClinicalTrials #HRSMarketReport #SyndicateReport #HRSMarketAnalysis #MarketReport
To view or add a comment, sign in
-
Join us for a free UCB-sponsored webinar on Wednesday, April 24, 2024, with Wendy Cantrell, DNP, CRNP, Kara Gooding, MMS, PA-C, Joe Gorelick, MSN, FNP-C, and Andrea Nguyen, PA-C, MPAS. - Get NP/PA perspectives and real-world insights as panelists present and discuss their own patient cases managed with IL-17 inhibitors. - Learn about the science of IL-17 inhibition and key therapeutic considerations for this growing class of biologic agents. - Explore the latest data on treatment outcomes with a focus on patient and prescriber expectations of “treatment success.” - Discover key considerations related to patient selection and screening, as well as treatment initiation and monitoring. Register for FREE: https://lnkd.in/eyckBZUu
To view or add a comment, sign in
-
-
𝐇𝐞𝐩𝐚𝐭𝐨𝐫𝐞𝐧𝐚𝐥 𝐒𝐲𝐧𝐝𝐫𝐨𝐦𝐞 (𝐇𝐑𝐒) 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 Our latest market report on Hepatorenal Syndrome (HRS) offers foundational insights into the technologies driving HRS diagnostics and therapeutics, emphasizing innovative solutions for precision in diagnosing and treating renal failure linked to chronic liver disease. The report presents a strategic framework for comprehensive HRS management, integrating diverse diagnostic methods and safety protocols to address healthcare challenges. The report highlights cutting-edge innovations in HRS technologies and explores the latest advancements in diagnostic techniques and therapeutic approaches. A global scenario analysis evaluates the worldwide implementation of HRS diagnostic tools, identifying emerging trends and investment prospects. Gain valuable insights into groundbreaking advances and patents in HRS diagnostics, market opportunities and challenges, current and future trends, pipeline progress, ongoing technological trials, and profiles of key players shaping HRS research. 𝐑𝐞𝐩𝐨𝐫𝐭 𝐋𝐢𝐧𝐤: https://lnkd.in/g-ijdPVs 𝐀𝐬𝐤 𝐟𝐨𝐫 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧: https://lnkd.in/d6q8Q-5a #HepatorenalSyndrome #HRS #MedicalInnovation #RenalFailure #LiverDisease #HealthcareAdvancements #MedicalResearch #ClinicalTrials #HRSMarketReport #SyndicateReport #HRSMarketAnalysis #MarketReport
To view or add a comment, sign in
-
The 2023 FTD Research Roundtable on Improving Efficiency and Power in FTD Clinical Trials run last month in Washington DC by The Association for Frontotemporal Degeneration (AFTD) was another great example of pre-competitive clinical and scientific meetings that push the field forward. Frank discussion from sponsors, clinician-scientists, and regulators was valuable. The program brought insight from regulators, scientific leaders, and advocates. and covered approaches to enable FTD clinical trials with fewer participants, from biomarkers for FTD clinical trials to clinical and surrogate outcome assessment measures, and disease progression modeling and statistical designs for a rare neurodegenerative disease. I'm grateful to The Association for Frontotemporal Degeneration (AFTD) for the invitation and support to speak on #digitalmarkers [importantly NOT digital 'bio'markers] as pressed by FDA rep Michelle Campbell - which I am in agreement. https://lnkd.in/e7hbd3fN #digitalanalytics #speech #clinicaltrials #dementia #ftd #pharma #medicalsciences #medicine #health
To view or add a comment, sign in
-
-
🔬 Exciting findings from the ENVISION trial: UBX1325 shows promise in advanced #wetAMD cases. Despite not meeting primary endpoint, it's safe and well-tolerated. Dr. raj maturi shares insights on its unique mechanism targeting senescent cells. Significant proportion of patients didn't require anti-VEGF treatment through 24 weeks. Secondary analysis hints at efficacy in longer disease duration patients. Ongoing exploration of combination therapy potential in Part B of ENVISION study. 👉 Learn more in this article from Healio by Michela Cimberle, fact checked by Christine Klimanskis #agerelatedmaculardegeneration #maculardegeneration #cataract #ophthalmology #ophthalmologynews
UBX1325 fails to meet noninferiority endpoint but performs better in longer-duration AMD
healio.com
To view or add a comment, sign in